


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on July 9, 2007.


Frank C. Eisenschenk, Ph.D., Patent Attorney

INFORMATION DISCLOSURE
STATEMENT

Examining Group 3743
Patent Application
Docket No. INN-122
Serial No. 10/539,828

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 3743
Applicants : Francois Romagne, Pascale Andre
Serial No. : 10/539,828
Filed : June 20, 2005
Conf. No. : 5861
For : Pharmaceutical Compositions Having an Effect on the Proliferation
of NK Cells and a Method Using the Same

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited references are enclosed.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

FCE/jps

Attachments: Form PTO/SB/08; copies of references cited therein.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/539,828	
			Filing Date	June 20, 2005	
			First Named Inventor	Francois Romagne	
			Art Unit	3743	
			Examiner Name		
Sheet	1	of	2	Attorney Docket Number	INN-122

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-6,979,546	12-27-2005	Moretta, <i>et al.</i>	All
	U2	US-2005-0221438	10-06-2005	Moretta, <i>et al.</i>	All
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	WO 01 36630	05-25-2001	Innate Pharma S.A.S.	All	
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/539,828
Filing Date	June 20, 2005
First Named Inventor	Francois Romagne
Group Art Unit	3743
Examiner Name	
Attorney Docket Number	INN-122

Sheet	2	of	2
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	SPAGGIARI, G.M. <i>et al.</i> "NK cell mediated lysis of autologous antigen-presenting cells is triggered by the engagement of the phosphatidylinositol 3-kinase upon ligation of the natural cytotoxicity receptors NKp30 and NKp46", <i>Eur. J. Immunol.</i> , 2001, pp. 1656-1665, Vol. 31, No. 6.	
	R2	MORETTA, A. <i>et al.</i> "Activating receptors and coreceptors involved in human natural killer cell-mediated cytotoxicity" <i>Ann. Rev. Immunol.</i> , 2001, pp.197-223, Vol. 19.	
	R3	MORETTA, A. <i>et al.</i> "Natural cytotoxicity receptors that trigger human NK-cell-mediated cytotoxicity" <i>Immunol. Today</i> , May 2000, pp. 228-234, Vol. 21, No. 5.	
	R4	CARSON, W.E. <i>et al.</i> "Interleukin-2 enhances the natural killer cell response to herceptin-coated Her2/Neu-positive breast cancer cells" <i>Eur. J. Immunol.</i> , 2001, pp. 3016-3025, Vol. 31.	
	R5	CARLENS, S. <i>et al.</i> "A new method for <i>in vitro</i> expansion of cytotoxic human CD3 ⁺ CD56 ⁺ natural killer cells" <i>Human Immunol.</i> , 2001, pp. 1092-1098, Vol. 62, No. 10.	
	R6	PARRISH-NOVAK, J. <i>et al.</i> "Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function" <i>Nature</i> , 2000, pp. 57-63, Vol. 408, No. 6808.	
	R7	ASANO, R. <i>et al.</i> "Antitumor activity of interleukin-21 prepared by novel refolding procedure from inclusion bodies expressed in <i>Escherichia coli</i> ", <i>FEBS Letters</i> , 2002, pp. 70-76, Vol. 528.	
	R8	NCBI database, GenBank Accession No. AJ223153.	
	R9	NCBI database, Genbank Accession No. AF031138.	
	R10		
	R11		
	R12		

Examiner Signature	/Michail Belyavskyi/ (02/20/2009)	Date Considered	
--------------------	-----------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/